Lyndra is a biopharmaceutical company that focuses on the development of long-acting oral therapies. Their proprietary technology platform aims to transform the administration of oral medications, enabling extended-release formulations that can last for a week or more.

Established in 2015, Quark Venture is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects.
 
Our strategic goal is to support and enable companies we invest in to grow, create value and be successful by providing not only financial support, but also developmental, infrastructure and expertise support, as needed, through our global network.
 
Our approach is to establish long-term relationships with target companies, with a view to enable and strengthen management to realize the full potential and value of the technology. This approach has previously been successfully demonstrated in the energy and high-tech sectors where Quark Venture partners have invested.
 
While Quark Venture is headquartered in Vancouver, it has offices in Boston, Hong Kong and Chengdu, and plans to establish a European office in 2017.

SQZ Biotech

COM:QUARKVENTURE

Lyndra

Analysis Not Available